Sr. Research Associate, Cas Nuclease Optimization

OPPORTUNITY
Mammoth's Discovery Team is seeking a Sr Research Associate to support its efforts to develop CRISPR-associated (Cas) nucleases for therapeutic genome editing applications. Discovery is a cross-disciplinary team of researchers responsible for the identification, screening and optimization of novel Cas nucleases. The successful candidate will be positioned in a downstream role within the team and will be responsible for executing experiments that push Cas nucleases into pre-clinical applications. The ideal candidate will have hands-on industry experience with genome editing in mammalian cells.
KEY RESPONSIBILITIES

• Execute experiments to evaluate and optimize Cas nucleases under the supervision of senior research staff
• Prepare protein, RNA, DNA and cell-based reagents for genome editing experiments
• Document and present experimental results at internal meetings
• Other duties as assigned

REQUIRED QUALIFICATIONS

• Bachelor's degree in molecular biology, cell biology or a related field
• 2 years industry experience executing genome editing experiments with Cas nucleases in mammalian cells
• Ability to execute mammalian cell tissue culture procedures independently in the lab

PREFERRED QUALIFICATIONS

• Molecular cloning experience
• Experience using NGS approaches to assay for genome editing
• Familiarity with advanced laboratory equipment (eg. automated liquid handlers, automated colony pickers, plate readers, FACS)
• Computer and scripting skills (Benchling, Geneious, JMP, SQL, R, Python)

BENEFITS

• Competitive salary with equity
• Company-paid health/vision/dental benefits
• Unlimited vacation and generous sick time
• Free breakfast/lunch/dinner/barista
• Free gym
• Public transportation commuter subsidy
• 401(k) matching

Mammoth Biosciences is harnessing the diversity of life to power the next generation of CRISPR products. Through the discovery and engineering of novel CRISPR systems, the company is enabling the full potential of its platform to read and write the code of life. Mammoth aims to develop permanent genetic cures through best-in-class in vivo and ex vivo therapies and to democratize disease detection with on-demand diagnostics. Mammoth can provide enhanced diagnostics and genome editing for life science research, healthcare, agriculture, biodefense and more. Based in the San Francisco Bay Area, Mammoth Biosciences is co-founded by CRISPR pioneer and Nobel Laureate Jennifer Doudna and Trevor Martin, Janice Chen, and Lucas Harrington. The firm is backed by top institutional investors including Redmile Group, Foresite Capital, Senator Investment Group, Sixth Street, Decheng, Mayfield, NFX, and 8VC, along with leading individual investors including Brook Byers, Tim Cook, and Jeff Huber.

TEAM
Our small-size proteins, such as Cas14 and CasPhi, are poised to transform disease treatment enabling novel editing approaches and delivery options that are difficult to achieve or not even possible with previously described CRISPR-Cas systems. Our teams are responsible for discovering and engineering novel CRISPR systems, establishing CRISPR-based diagnostics, and translating our unique CRISPR technology into therapeutic treatments with the ultimate goal of cures for indications with high medical need.

It is our policy and intent to provide equal opportunity to all persons without regard to race, color, religion, political affiliation, sex/gender (including gender expression/identity, pregnancy, childbirth and related medical conditions), marital status, registered domestic partner status, sexual orientation, age, ancestry, national origin, veteran status, disability, medical condition, genetic characteristics, and/or any other basis protected by law. This policy covers all facets of employment including, but not limited to: recruitment, selection, placement, promotions, transfers, demotions, terminations, training, and compensation.